Don't miss our weekly PhD newsletter | Sign up now Don't miss our weekly PhD newsletter | Sign up now

  Antibodies that redirect T cells to kill aggressive lymphomas


   College of Life Sciences

This project is no longer listed on FindAPhD.com and may not be available.

Click here to search FindAPhD.com for PhD studentship opportunities
  Dr H Walter  No more applications being accepted  Competition Funded PhD Project (Students Worldwide)

About the Project

Whilst most patients with  diffuse large B cell lymphoma (DLBCL) are cured with immunochemotherapy, patients who fail to respond or who relapse early die from uncontrolled disease within months.  Monoclonal antibodies are widely used in the treatment of cancer, including DLBCL.  Recent developments in technology and understanding of the immune system, have enabled the generation of bispecific antibodies, that can simultaneously bind to different antigens and redirect the immune system towards targeted killing of tumour cells. Such bispecific antibodies have shown remarkable activity in preliminary clinical trials.  In combination with Isogenica (Cambridge) we are developing and assessing novel bispecific and trispecific antibodies for therapy of DLBCL.

This project provides an exciting opportunity to be involved in cutting edge research at the cancer-immunology interface, incorporating research in advanced therapeutics, precision medicines and diagnostics discovery.  You will be working on a unique platform developed by Isogenica, gaining experience in antibody discovery in haematological malignancies utilising cutting edge techniques, and characterise these within Isogenica’s state of the art facilities.  Studies of the biological function of these antibodies will be undertaken and you will have the opportunity to learn a diverse set of laboratory and bio-informatics skills, through cross-institutional working, gaining expertise in cell culture, flow cytometry, cell viability assays, CyTOF and single cell sequencing. 

Throughout the studentship, you will be embedded within the Ernest and Helen Scott Haematological Research Institute, at the UoL, which has existing research strengths in B cell malignancies and understanding of the role of the immune system in the treatment of DLBCL. 

Entry requirements:

Please see for relevant text: https://more.bham.ac.uk/mrc-impact/phd-opportunities/

Academic requirement

Minimum qualifications and experience to undertake a research degree are detailed in the QAA UK Quality for Higher Education. For some subject areas, there is also an expectation that an individual will have undertaken a Masters qualification before beginning a doctoral programme. Candidates should possess the relevant qualifications and/or experience to demonstrate a capability to undertake a doctorate, which will be assessed during the recruitment process. More details can be found on the MRC website (https://mrc.ukri.org/skills-careers/studentships/studentship-guidance/student-eligibility-requirements/).

Residency requirements

These studentships are available to UK nationals, EU nationals and international applicants. Full details on eligibility, including residence requirements can be found on the Full Eligibility Criteria (https://more.bham.ac.uk/mrc-impact/wp-content/uploads/sites/27/2020/11/Full-Eligibility-Criteria.pdf) or on the UKRI website (https://www.ukri.org/our-work/developing-people-and-skills/find-studentships-and-doctoral-training/get-a-studentship-to-fund-your-doctorate/).

To apply https://more.bham.ac.uk/mrc-impact/phd-opportunities/

Biological Sciences (4)

Funding Notes

- fees (at UK rate)
- tax free stipend of at least £15,295 p.a (to rise in line with UKRI recommendation)
- a travel allowance in year 1
- a travel / conference budget
- a generous consumables budget
- use of a laptop for the duration of the programme.

https://more.bham.ac.uk/mrc-impact/phd-opportunities/
Search Suggestions
Search suggestions

Based on your current searches we recommend the following search filters.